Injection therapy for erectile dysfunction

Edward Kim, L. I. Lipshultz

Research output: Contribution to journalReview article

Abstract

The use of intracavernous injection therapy to produce erections, first described in 1983, has been a major advance in the treatment of erectile dysfunction. In this procedure, vasoactive substances, either as a single agent or in combination, are injected directly into the corporeal bodies of the penis. The resultant arterial and trabecular smooth muscle relaxation causes an increased arterial inflow and decreased venous outflow. The injected dose is carefully adjusted so that the erection may spontaneously resolve after approximately one hour. This form of injection therapy is applicable for most causes of erectile dysfunction (vasculogenic, psychogenic, neurologic), and it is highly successful in producing effective erections. Although patient satisfaction is generally high, drop-out rates are often attributable to reluctance to self-inject and associated discomfort secondary to the injection or the substances used. Complications, although rare, include prolonged erections (priapism) and tunical plaque formation. Injection therapy has become within the last decade a first-line therapy for erectile dysfunction and now offers many men a non-operative, minimally invasive treatment alternative.

Original languageEnglish (US)
Pages (from-to)116-120
Number of pages5
JournalJournal of the Irish Colleges of Physicians and Surgeons
Volume26
Issue number2
StatePublished - Jan 1 1997

Fingerprint

Erectile Dysfunction
Injections
Therapeutics
Priapism
Muscle Relaxation
Penis
Patient Satisfaction
Nervous System
Smooth Muscle

All Science Journal Classification (ASJC) codes

  • Medicine(all)

Cite this

Injection therapy for erectile dysfunction. / Kim, Edward; Lipshultz, L. I.

In: Journal of the Irish Colleges of Physicians and Surgeons, Vol. 26, No. 2, 01.01.1997, p. 116-120.

Research output: Contribution to journalReview article

@article{1e2c0ff8ad684d4bb1a9991d272d4c28,
title = "Injection therapy for erectile dysfunction",
abstract = "The use of intracavernous injection therapy to produce erections, first described in 1983, has been a major advance in the treatment of erectile dysfunction. In this procedure, vasoactive substances, either as a single agent or in combination, are injected directly into the corporeal bodies of the penis. The resultant arterial and trabecular smooth muscle relaxation causes an increased arterial inflow and decreased venous outflow. The injected dose is carefully adjusted so that the erection may spontaneously resolve after approximately one hour. This form of injection therapy is applicable for most causes of erectile dysfunction (vasculogenic, psychogenic, neurologic), and it is highly successful in producing effective erections. Although patient satisfaction is generally high, drop-out rates are often attributable to reluctance to self-inject and associated discomfort secondary to the injection or the substances used. Complications, although rare, include prolonged erections (priapism) and tunical plaque formation. Injection therapy has become within the last decade a first-line therapy for erectile dysfunction and now offers many men a non-operative, minimally invasive treatment alternative.",
author = "Edward Kim and Lipshultz, {L. I.}",
year = "1997",
month = "1",
day = "1",
language = "English (US)",
volume = "26",
pages = "116--120",
journal = "Surgeon",
issn = "1479-666X",
publisher = "Elsevier Limited",
number = "2",

}

TY - JOUR

T1 - Injection therapy for erectile dysfunction

AU - Kim, Edward

AU - Lipshultz, L. I.

PY - 1997/1/1

Y1 - 1997/1/1

N2 - The use of intracavernous injection therapy to produce erections, first described in 1983, has been a major advance in the treatment of erectile dysfunction. In this procedure, vasoactive substances, either as a single agent or in combination, are injected directly into the corporeal bodies of the penis. The resultant arterial and trabecular smooth muscle relaxation causes an increased arterial inflow and decreased venous outflow. The injected dose is carefully adjusted so that the erection may spontaneously resolve after approximately one hour. This form of injection therapy is applicable for most causes of erectile dysfunction (vasculogenic, psychogenic, neurologic), and it is highly successful in producing effective erections. Although patient satisfaction is generally high, drop-out rates are often attributable to reluctance to self-inject and associated discomfort secondary to the injection or the substances used. Complications, although rare, include prolonged erections (priapism) and tunical plaque formation. Injection therapy has become within the last decade a first-line therapy for erectile dysfunction and now offers many men a non-operative, minimally invasive treatment alternative.

AB - The use of intracavernous injection therapy to produce erections, first described in 1983, has been a major advance in the treatment of erectile dysfunction. In this procedure, vasoactive substances, either as a single agent or in combination, are injected directly into the corporeal bodies of the penis. The resultant arterial and trabecular smooth muscle relaxation causes an increased arterial inflow and decreased venous outflow. The injected dose is carefully adjusted so that the erection may spontaneously resolve after approximately one hour. This form of injection therapy is applicable for most causes of erectile dysfunction (vasculogenic, psychogenic, neurologic), and it is highly successful in producing effective erections. Although patient satisfaction is generally high, drop-out rates are often attributable to reluctance to self-inject and associated discomfort secondary to the injection or the substances used. Complications, although rare, include prolonged erections (priapism) and tunical plaque formation. Injection therapy has become within the last decade a first-line therapy for erectile dysfunction and now offers many men a non-operative, minimally invasive treatment alternative.

UR - http://www.scopus.com/inward/record.url?scp=0030904180&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030904180&partnerID=8YFLogxK

M3 - Review article

AN - SCOPUS:0030904180

VL - 26

SP - 116

EP - 120

JO - Surgeon

JF - Surgeon

SN - 1479-666X

IS - 2

ER -